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Abstract
T helper type 17 (Th17) lymphocytes, characterized by the production of interleukin-17 and
other pro-inflammatory cytokines, are present in intestinal lamina propria and have been
described as important players driving intestinal inflammation. Recent evidence, supporting
the notion of a functional and phenotypic instability of Th17 cells, has shown that Th17 dif-
ferentiate into type 1 regulatory (Tr1) T cells during the resolution of intestinal inflammation.
Moreover, it has been suggested that the expression of CD39 ectonucleotidase endows
Th17 cells with immunosuppressive properties. However, the exact role of CD39 ectonu-
cleotidase in Th17 cells has not been studied in the context of intestinal inflammation. Here
we show that Th17 cells expressing CD39 ectonucleotidase can hydrolyze ATP and survive
to ATP-induced cell death. Moreover, in vitro-generated Th17 cells expressing the CD39
ectonucleotidase produce IL-10 and are less pathogenic than CD39 negative Th17 cells in
a model of experimental colitis in Rag-/- mice. Remarkably, we show that CD39 activity regu-
lates the conversion of Th17 cells to IL-10-producing cells in vitro, which is abrogated in the
presence of ATP and the CD39-specific inhibitor ARL67156. All these data suggest that
CD39 expression by Th17 cells allows the depletion of ATP and is crucial for IL-10 produc-
tion and survival during the resolution of intestinal inflammation.
Introduction
T helper 17 (Th17) cells play a fundamental protective role against infections caused by fungi
and extracellular bacteria [1,2]. Th17 cells have been associated with inflammation and the
pathogenesis of several autoimmune diseases in mice and humans [1], such as experimental
autoimmune encephalomyelitis (EAE) [3], experimental colitis [4,5] and human inflammatory
bowel disease (IBD) [6–10].
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Th17 cells are endowed with remarkable functional plasticity, being able to differentiate into
Th1 cells in lymphopenic hosts, during EAE and in antitumor immune responses [11–15]. Some
groups have also reported the presence of IFN- γ -producing Th17 cells in humans and patients
with Crohn’s disease [16,17]. Th17 cells can also differentiate into IL-10-producing cells during
the resolution of inflammation [18–20]. Interestingly, using fate mapping mouse models, Flavell
and colleagues have recently demonstrated that in the course of an inflammatory immune
response, Th17 cells can transdifferentiate into type 1 regulatory T (Tr1) cells [21].
Two distinct types of Th17 cells have been defined: pathogenic or encephalitogenic Th17
cells and the so-called non-pathogenic Th17 cells. Some reports have demonstrated that Th17
cells generated with TGF-β1 and IL-6 are not pathogenic in the setting of EAE [18], whereas
Th17 cells produced with IL-23 and without TGF-β1 are highly pathogenic in the same model
[22–24]. Depending on the experimental setting, different cytokines produced by Th17 cells
seem to drive their effector function. For instance, in tumor immunity, the production of IFN-
γ by Th17 cells has proved to be determining the potential of Th17 cells to eradicate an estab-
lished tumor [14]. Other studies revealed that the encephalitogenic properties of Th17 cells
depend on GM-CSF production [23,25], whereas IL-10 production has been strongly related to
non-pathogenic Th17 cells in EAE [18]. Moreover, IL-10 production by Th17 cells has been
strongly related to the acquisition of regulatory properties by Th17 cells and the resolution of
intestinal inflammation [20,21].
Extracellular ATP (eATP) is a danger signal released by dying and damaged cells, and it
functions as an immunostimulatory signal that promotes inflammation [26,27]. eATP can be
sensed by purinergic P2 receptors including the cation-selective receptor channels (P2X) and
metabotropic G protein-coupled receptors (P2Y) [28]. eATP has been shown to engage P2
receptors on T cells to induce Th17 differentiation [29]. On the other hand, high doses of
eATP induces necrotic lysis through P2X7 receptor signaling in T cells [30,31].
CD39 (NTPDase-1) and CD73 (ecto-5’-nucleotidase) ectonucleotidases are two cell-surface
ectoenzymes that dephosphorylate ATP into its metabolites ADP, AMP and adenosine thus
shifting the balance from inflammatory to suppressive microenvironments [32]. Recently, it
has been reported that ATP signaling through P2X7 receptor inhibits the conversion of naive T
cells to Tr1 cells and that CD39 can promote Tr1 differentiation through eATP hydrolysis [33].
It is have been described that Th17 cells generated with TGF-β1 and IL-6 express CD39 and
CD73 ectonucleotidases endowing these cells with the capacity to produce adenosine and pro-
mote immunosuppressive microenvironments [34]. However, the role of CD39 expression in
other aspects such as in depleting eATP to reduce P2X7 receptor-mediated cytotoxicity or pro-
moting the plasticity of this subset of T cells has not been explored. In the current study, we
present a comprehensive comparison of in vitro-generated Th17 cells expressing high and low
levels of CD39 and CD73 ectonucleotidases. We found that Th17 cells generated with TGF-β1
(Th17TGF-β1) which express the CD39 and CD73 ectonucleotidases and Th17 cells generated
with IL-23 (Th17IL-23) which do not express these ectonucleotidases constitute two fundamen-
tally different Th17 subsets, evidenced at the transcriptional level and by the types of cytokines
they secrete. In agreement with their transcriptional profile, Th17TGF-β1 cells were significantly
less pathogenic than Th17IL-23 cells in a model of experimental colitis, as they induce a tran-
sient reduction in weight loss in Rag-/- mice and the production of IL-10 in the intestine. Inter-
estingly, Th17TGF-β1 cells can hydrolyze ATP in a CD39-dependent manner, providing
Th17TGF-β1 cells a superior survival capacity when exposed to high levels of ATP. Furthermore,
here we show that Th17TGF-β1 cells produce higher levels of IL-10 than Th17IL-23 cells when
reactivated in vitro in the presence of Tr1-polarizing cytokines. Finally, we report that CD39
activity is important for IL-10 production by Th17TGF-β1 cells since CD39 inhibition using the
specific inhibitor ARL67156 reduced IL-10 production by in vitro re-activated Th17 cells.
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Materials and Methods
Mice
C57BL/6, B6SJL-PTPRC (CD45.1), OT-II, IL-17-GFP, Rag1-/-, P2X7R-/- mice were purchased
from The Jackson Laboratory. All mice were kept in an animal facility under standard housing
guidelines. Animal work was carried out under institutional regulations of Fundación Ciencia
& Vida and was approved locally by the ethical review committee of the Facultad de Ciencias,
Universidad de Chile.
Generation of Th17 cells
CD4+ T cells were purified from spleens of IL-17-GFP and P2X7R-/- mice. The spleen was per-
fused with RPMI + 10% FCS, and CD4+ T cells were positively selected using anti-CD4 MACS
(Miltenyi Biotec) following the manufacturer’s instructions. CD4+ T cells were cultured in a
96-well flat bottom microplate (0.1 x 106 CD4+ T cells/well) and were activated with plate-
bound a-CD3 (2 μg/ml; clone 145-2C11, eBioscience) and a-CD28 (2 μg/ml; clone 37.51) for 4
days in the presence of different cytokine cocktails. To generate Th17TGF-β1 cells, CD4+ T cells
were differentiated in the presence of 2 ng/ml recombinant human TGF-β1 (eBioscience), 20
ng/ml recombinant mouse IL-6 (eBioscience), 10 ng/ml IL-1β (eBioscience) and 5 μg/ml of
anti-IFN-γ (clone XMG1.2, Biolegend) and then reactivated for another 3 days in the presence
of 2 ng/ml recombinant human TGF-β1 (eBioscience) and 20 ng/ml recombinant mouse IL-6
(eBioscience). Th17IL-23 cells were differentiated in the presence of 2 ng/ml recombinant
human TGF-β3 (eBioscience), 20 ng/ml recombinant mouse IL-6 (eBioscience), 10 ng/ml IL-
1β (eBioscience) and 5 μg/ml of anti-IFN-γ (clone XMG1.2, Biolegend) and then reactivated in
the presence of 20 ng/ml recombinant mouse IL-6 (eBioscience), 10 ng/ml IL-1β (eBioscience)
and 25 ng/ml recombinant mouse IL-23 (Biolegend). Cells were then isolated by cell sorting for
adoptive transfer experiments, RNA extraction, intracellular cytokine staining and flow
cytometry.
Induction of colitis in Rag-/- mice
For experimental colitis experiments, 1.3x106 Th17TGF-β1 or Th17IL-23 cells were sorted based
on IL-17 production (GFP+) and then transferred into Rag-/- mice. The body weight was mea-
sured every 2 days. Six weeks after adoptive transfer, the mice were sacrificed, and the entire
colon was removed from cecum to anus. The colon length was measured as an indicator of
inflammation. Clinical score was calculated based on weight loss and colon length. Weight-loss
scores were determined as 0 = 0–2.5% weight loss; 1 = 2.5–5% weight loss; 2 = 5–7.5% weight
loss; 3 = 7.5–10% weight loss; and 4 =>10% weight loss. This score was calculated using the
weight of each mouse at the end point. Each weight data was compared to the average weight
of control group. Colon length scores were determined as 0 = no colon size reduction;
1 = 0–5% colon size reduction; 2 = 5–10% colon size reduction; 3 = 10–15% colon size reduc-
tion; and 4 =>15% colon size reduction. This score was calculated using colon length normal-
ized by the weight of each mouse. For each mouse, these scores were combined and divided by
two to give an overall clinical score ranging from 0 (healthy) to 4 (maximal colitis).
Analysis of transferred cells in Rag-/- mice
Six to eight weeks after adoptive transfer of Th17TGF-β1 or Th17IL-23 cells into Rag-/- mice, the
mice were sacrificed and lymphoid organs and lamina propria were dissected. The cells were
analyzed by flow cytometry to assess the percentage of the transferred cells (CD3+ CD4+)
within a lymphoid gate and the production of cytokines by intracellular cytokine staining.
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Intracellular staining and flow cytometry
Cells obtained from lamina propria, lymph nodes and in vitro-generated Th17 cells were re-
stimulated with 0.25 μM PMA (Sigma-Aldrich) and 1 μg/ml ionomycin (Sigma-Aldrich) in the
presence of GolgiPlug (BD Biosciences) for 4 h. Cells were stained with antibodies against the
cell surface markers CD4, CD39, CD73, and then resuspended in a fixation/permeabilization
solution (Cytofix/Cytoperm; BD Pharmingen). Following fixation and permeabilization, the
cells were incubated with antibodies against IFN-γ, IL-17 and IL-10 for 30 min at 4°. The cells
were then washed with permeabilization buffer and resuspended in PBS + 2% FCS for FACS
analysis (FACSCanto II; BD Bioscience). In some cases, Fixable Viability Dye (eBioscience)
was used to discard dead cells from the analysis. Analysis of FACS data was performed using
the FLOWJO software (Tree Star Inc., Ashland, OR).
Cytokine secretion measurements
Th17TGF-β1 or Th17IL-23 cells were activated for 3 h at 1x10
6 cells/ml with 0.25 μM PMA
(Sigma-Aldrich) and 1 μg/ml ionomycin (Sigma-Aldrich). After activation, the supernatants
were harvested and analyzed using the mouse Th1/Th2/Th17 CBA Kit (BD Biosciences), fol-
lowing the manufacturer’s instructions. GM-CSF was analyzed by ELISA using the BD OptEIA
kit (BD Biosciences, 555167).
To analyze the cytokines produced in the intestine of Rag-/- mice transferred with Th17 cells,
the intestine was cut into fragments of 1 cm of length and incubated in 1 ml IMDM + 10% FCS
for 24 h at 37°C and 5% CO2. The medium was collected and centrifuged at 600 x g for 7 min.
The supernatant was analyzed using the CBA Kit Mouse Th1/Th2/Th17 (BD Biosciences).
qPCR
Th17 cells were isolated by cell sorting, and total RNA was obtained using EZNA Total RNA
Kit I (O Bio-Tek). 1 μg of RNA was reverse transcribed using M-MLV reverse transcriptase
(Invitrogen). The PCR reaction was performed using Brilliant II SYBR Green QPCRMaster
Mix (Agilent Technologies) in a Stratagene Mx3000P real-time PCR machine. For relative
quantitation, the amplified fragments were normalized according to constitutive transcription
of the housekeeping gene GAPDH. The sequences of the primers used for quantification of
each measured transcript were the following:
rorc forward 5’-CAGAGGAAGTCAATGTGGGA-3’,
reverse 5’-GTGGTTGTTGGCATTGTAGG-3’;
tbx21 forward 5’-CCTGTTGTGGTCCAAGTTCAAC-3’
reverse 5’-CACAAACATCCTGTAATGGCTTGT-3’;
il17a forward 5’TTCATCTGTGTCTCTGATGCT-3’
reverse 5’-AACGGTTGAGGTAGTCTGAG-3’;
il9 forward 5’-CTGATGATTGTACCACACCGTGC-3’
reverse 5’-GCCTTTGCATCTCTGTCTTCTGG-3’;
il10 forward 5’GAAGACAATAACTGCACCCA-3’
reverse 5’-CAACCCAAGTAACCCTTAAAGTC-3’;
Il22 forward 5’GACAGGTTCCAGCCCTACAT-3’
reverse 5’ATCGCCTTGATCTCTCCACT-3’;
csf2 forward 5’ACCACCTATGCGGATTTCAT-3’
reverse 5’TCATTACGCAGGCACAAAAG-3’;
ifng forward 5’GAGCCAGATTATCTCTTTCTACC-3’
reverse 5’GTTGTTGACCTCAAACTTGG-3’;
grzb forward 5’ATCAAGGATCAGCAGCCTGA-3’
Purinergic Signaling in Th17 Cell Plasticity
PLOS ONE | DOI:10.1371/journal.pone.0157889 June 20, 2016 4 / 16
reverse 5’TGATGTCATTGGAGAATGTCT-3’;
ahr forward 5’-CAGCAGATGCCTTGGTCTTCT-3’
reverse 5’-ATACGCTCTGATGGATGACATCA-3’;
cmaf forward 5’-AGCAGTTGGTGACCATGTCG-3’
reverse 5’-TGGAGATCTCCTGCTTGAGG-3’;
p2rx7 forward 5’-CCAGGAAGCAGGAGAGAACTT-3’
reverse 5’-ATCCGTGTTCTTGTCATCCAG-3’;
hprt forward 5’-CTCCTCAGACCGCTTTTTGC-3’
reverse 5’-TAACCTGGTTCATCATCGCTAATC-3’;
gapdh forward 5’TCCGTGTTCCTACCCCCAATG-3’
reverse 5’GAGTGGGAGTTGCTGTTGAAG-3’.
Determination of ATP/AMP hydrolysis by HPLC
The enzymatic activity of CD39 and CD73 was evaluated based on the percentage of hydrolysis
of ATP or AMP respectively by HPLC. Briefly, Th17 cells generated in vitro were diluted in
Hanks’ balanced salt solution (HBSS) and incubated in a 96- well flat-bottom plates at 0.5x105
cells/well with 10 μMATP (Sigma-Aldrich) in the presence or absence of the CD39 inhibitor
ARL67156 (Sigma-Aldrich) at a concentration of 50 μM or with 10 μMAMP (Sigma-Aldrich),
with or without the CD73 inhibitor APCP (Adenosine 5’-(a,b-methylene) diphosphate)
(50 μM) (Sigma-Aldrich). After 1 h, the cells were harvested, transferred to ice for 15 min, and
then centrifuged at 1000 x g for 10 min. Supernatants were collected and stored at -20°C until
further analysis. HPLC analysis was carried out in a Water Breeze system using an anion
exchanger column (Mono Q; GE Healthcare, Chalfont St Giles, UK). The mobile phase used
consisted of a linear gradient from buffer A (Tris–HCl 100 mM, pH 7.8) to buffer B (Tris–HCl
100 mM, NaCl 1 M, pH 7.8). The effluent was monitored at 257 nm using an online UV detec-
tor. The column was calibrated using ATP, AMP and adenosine as standards.
Determination of Th17 cell survival in high concentrations of ATP
Th17 cells isolated by cell sorting were resuspended at 1x105 cells/well in HBSS medium. Cells
were cultured in the presence or absence of ATP (100, 500 or 1000 μM) (Sigma-Aldrich) for 30
min at 37°C and 5% CO2. Cells were then harvested and centrifuged at 600 x g for 7 min and
resuspended in 100 μL of Binding Buffer (10 mMHEPES, 140 mMNaCl, 2.5 mM CaCl2, pH
7.4) containing 0.5 μL of Annexin V APC (Biolegend) and 2 μL of propidium iodide (50 μg/
mL) (Sigma). Cells were incubated for 20 min at room temperature and 300 μL of Binding
Buffer was added. Live and dead cells were analyzed by flow cytometry.
Statistical analysis
Data are presented as mean ± SEM. Differences between groups were determined using Mann-
Whitney test or two-tailed t-test. Where indicated, differences were analysed using Kruskal-
Wallis or two-way analysis of variance paired with Bonferroni post-tests. Statistical analysis
and graphs were obtained with GRAPHPAD PRISM (GraphPad Software Inc., La Jolla, CA).
Results
In vitrogenerated Th17 cells expressing high levels of CD39
ectonucleotidase present a regulatory phenotype
To evaluate a putative role of CD39 and CD73 in Th17 cells we generated Th17 cells expressing
high or low levels of these ectonucleotidases. It has been reported that TGF-β1 induces CD39
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and CD73 expression in Th17 cells; however after a second round of restimulation in the
absence of TGF-β1, Th17 cells lose ectonucleotidase expression [34]. For this reason, we gener-
ated Th17 cells using two rounds of activation. Th17 cells expressing high levels of CD39 and
CD73 were generated with TGF-β1, IL-6, and IL-1β, and reactivated in the presence of TGF-β1
and IL-6 (Th17TGF-β1). Th17 cells expressing low levels of ectonucleotidases were generated
with TGF-β3, IL-6, and IL-1β, and reactivated in the presence of IL-6, IL-1β, and IL-23
(Th17IL-23). As shown in Fig 1A and 1B, a similar percentage of IL-17 producing cells were
obtained in Th17TGF-β1 and Th17IL-23 culturing conditions. Accordingly, Th17TGF-β1 and
Th17IL-23 cells expressed similar levels of RORγt, the master transcription factor of Th17 cells
and neither expressed GATA-3 nor Foxp3 transcription factors. Interestingly, although it has
been reported that Th17 cells generated with IL-23 express higher levels of T-bet than cells gen-
erated with TGF-β1 [24,35], in our setting Th17TGF-β1 cells expressed higher levels of this mas-
ter transcription factor compared to Th17IL-23 cells (Fig 1C and 1D).
Next, we analyzed CD39 and CD73 expression by these in vitro-generated Th17 cells. As
expected, Th17TGF-β1 cells acquired high levels of CD39 and CD73 ectonucleotidases expres-
sion whereas Th17IL-23 cells presented low expression of both ectonucleotidases (Fig 1E and
1F). A fraction of Th17TGF-β1 cells (approx. 25%) also expressed significant levels of CD49b
and Lag-3, markers of Tr1 cells [36], whereas a fraction of Th17IL-23 cells only expressed Lag-3.
Although a fraction of Th17TGF-β1 cells showed Tr1 markers, these do not constitute bona fide
Tr1 cells, since they express RORγt transcription factor and produce IL-17. Although both
Th17 cell subsets expressed CCR6, Th17TGF-β1 cells showed lower levels of this chemokine
receptor compared to Th17IL-23 cells (Fig 1G and 1J).
We further investigated the expression of Th17-associated genes in Th17TGF-β1 and Th17IL-23
cells. The expression of mRNAs encoding T-bet, IFN-γ, IL-9, AHR, c-Maf and IL-10 was higher
in Th17TGF-β1 cells whereas expression of mRNAs encoding GM-CSF and IL-22 was higher in
Th17IL-23 cells (Fig 2A). Interestingly, following in vitro reactivation, Th17TGF-β1 cells secreted
higher levels of IL-10, and lower levels of IL-17, GM-CSF, TNF, IL-2 compared to Th17IL-23 cells
(Fig 2B–2D). Taken together, these results strongly suggest that Th17TGF-β1 cells rapidly lose
their inflammatory potential and present a regulatory phenotype upon reactivation.
In vitrogenerated Th17 cells expressing high levels of CD39 and CD73
can hydrolyze ATP and survive to ATP-induced death
We next tested the enzymatic activity of CD39 and CD73 ectonucleotidases in Th17 cells. As
shown in Fig 3A–3D, only Th17TGF-β1 cells, which express the CD39 and CD73 ectonucleotidases,
can hydrolyze ATP and AMP. Moreover, ATP hydrolysis was partially blocked in Th17TGF-β1
cells by inhibiting CD39 enzymatic activity using the ecto-ATPase inhibitor ARL67156 while
adenosine production was blocked using the CD73 inhibitor APCP in these cells.
As Th17TGF-β1 cells express the CD39 and CD73 ectonucleotidases and produce adenosine,
we tested whether these cells present suppressive capacity in vitro. For this, Th17TGF-β1 or
Th17IL-23 cells were sorted based on IL-17-GFP expression and co-cultured with Violet-labeled
CD4+ effector T cells from OT-II mice activated with OVA323-339 and antigen presenting cells
for 3 days. As shown in S1 Fig, both Th17TGF-β1 and Th17IL-23 cells displayed a low suppressive
capacity only when co-cultured in direct contact with effector cells at high Th17/Teff ratios
(1:1). No suppression was observed when the cells were cultured using transwell chambers (S1
Fig), suggesting that soluble factors such as adenosine are not involved in this process.
Since Th17TGF-β1 cells can hydrolyze ATP, we sought to determine whether these cells were
more resistant to ATP-induced cell death. As shown in Fig 3E and 3F, Th17TGF-β1 cells were
more resistant than Th17IL-23 cells to rapid cell death induced by high doses of ATP
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Fig 1. In vitro-generated Th17TGF-β1 but not Th17IL-23 cells express CD39 and CD73 ectonucleotidases. (A) IL-17-GFP expression in Th17
cells differentiated in the presence of TGF-β1 and IL-6 (Th17TGF-β1 cells) or IL-23, TGF-β3 and IL-1β (Th17IL-23 cells). (B) Percentage of IL-
17-GFP+ cells among total CD4+ cells (n = 12). (C and D) FACS analysis and mean fluorescence intensity for RORγt, T-bet, GATA-3 and Foxp3
transcription factors in IL-17-GFP+ Th17 cells (n = 4). (E and F) Representative FACS analysis and mean fluorescence intensity for CD39 and
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(>500μM). Since both types of Th17 cells express similar levels of the mRNA encoding the
P2X7 receptor (Fig 3G), this suggests that ATP signaling through the P2X7 receptor is reduced
CD73 ectonucleotidases (n = 7). (G) CD49b and Lag-3 (n = 4) expression in IL-17-GFP+ Th17 cells. (H) Percentage of CD49b+/Lag-3+ cells and
percentage of CD49b-/Lag-3+ cells in IL-17-GFP+ Th17 cells (n = 4). (I and J) CCR6 expression in IL-17-GFP+ Th17 cells (n = 6). Data are
presented as mean ± S.E.M. *p<0.05 and ***p<0.001 determined by t-test (B and F) or Mann-Whitney test (D, G and I).
doi:10.1371/journal.pone.0157889.g001
Fig 2. Th17TGF-β1 cells present a regulatory phenotype. (A) IL-17-GFP+ Th17TGF-β1 and Th17IL-23 cells were sorted and then analyzed by real-
time PCR for mRNA expression of several transcription factors and cytokines (n = 3). (B) IL-17-GFP+ Th17TGF-β1 and Th17IL-23 cells were sorted
and then reactivated for 4 hrs with PMA plus ionomycin to assess cytokine production by CBA or (C) in the presence of PMA, ionomycin and
brefeldin A to analyze GM-CSF production by FACS (n = 5). (D) Percentage of GM-CSF+ cells within IL-17-GFP+ Th17TGF-β1 and Th17IL-23 cells
(n = 5). Data are presented as mean ± S.E.M. *p<0.05, **p<0.01 and ***p<0.001 determined by t-test (A) or Mann-Whitney test (B and D).
doi:10.1371/journal.pone.0157889.g002
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in Th17TGF-β1 cells due to CD39 activity. These results also raise the possibility that CD39
expression confers Th17TGF-β1 cells with a superior survival capacity when faced with toxic
doses of ATP.
In vitrogenerated Th17 cells expressing high levels of CD39
ectonucleotidase convert to IL-10 producing cells during intestinal
inflammation
It has been reported that Th17 cells generated with TGF-β1 and IL-6 are less pathogenic
than Th17 cells differentiated with IL-23 [18]. To evaluate the pathogenicity of our Th17
cells in a model of experimental colitis, we transferred Th17TGF-β1 or Th17IL-23 cells into
Rag-/- mice and measured body weight loss and colon length in these mice. As shown in Fig
4A, mice treated with Th17TGF-β1 cells started losing body weight 3 weeks after adoptive
transfer whereas mice transferred with Th17IL-23 cells presented a delay in the onset of
weight loss and started losing weight 5 weeks following adoptive transfer. Moreover, Rag-/-
mice treated with Th17TGF-β1 cells presented a transient weight loss and began to recover
by week 5, whereas mice treated with Th17IL-23 cells presented severe weight loss and had
to be sacrificed by 6 weeks after the adoptive transfer (Fig 4A). In agreement with the severe
and persistent weight loss, mice treated with Th17IL-23 cells presented a significant reduc-
tion in the colon length compared to mice receiving PBS (Fig 4B). Although not statistically
significant, mice treated with Th17TGF-β1 cells presented a lower clinical score compared to
mice treated with Th17IL-23 cells (Fig 4C). H&E and alcian blue staining of distal colonic
sections revealed severe wall thickening, extensive leukocyte infiltration, and disruption of
intestinal crypts and goblet cells in mice treated with Th17TGF-β1 or Th17IL-23 cells com-
pared to controls (Fig 4D). This suggests that although mice treated with Th17TGF-β1 cells
recover and gain weight, the damage to the colon is not reversed in these mice at this time
point.
In agreement with the less severe body weight loss, mice treated with Th17TGF-β1 cells secreted
higher levels of IL-10 as determined directly in their small intestine compared to mice treated
with Th17IL-23 cells (Fig 4E). We next analyzed the stability of Th17TGF-β1 and Th17IL-23 cells 6
weeks after adoptive transfer and found that both Th17 cell subsets lost IL-17 production and a
significant fraction of transferred cells produced IFN-γ (Fig 4G). Notably, a small fraction of
transferred Th17TGF-β1 cells, but not of Th17IL-23 cells, were able to produce IL-10 (Fig 4F). The
differences observed in body weight loss were not due to a differential capacity of of Th17TGF-β1
and Th17IL-23 cell subsets to survive or persist in the host, since both populations were found at
similar percentages within spleen, mesenteric lymph nodes and small intestine lamina propria up
to 8 weeks following adoptive transfer into Rag-/- mice (S2 Fig). Taken together, these data sug-
gest that Th17TGF-β1 cells are able to induce the production of IL-10 in the intestine of Rag
-/-
mice and can convert into IL-10-producing cells during the recovery from intestinal inflamma-
tion, which may explain the transient weight loss observed in mice treated with Th17TGF-β1 cells.
Fig 3. Th17TGF-β1 but not Th17IL-23 cells hydrolyze ATP to adenosine in a CD39-and CD73-dependent manner and
survive in the presence of high doses of ATP. IL-17-GFP+ Th17TGF-β1 and Th17IL-23 cells were sorted and cultured for 1 hr
with 10 μMATP in the presence of 50 μMARL67156 or 50 μMAPCP. Supernatants were then analyzed by HPLC to assess (A
and B) ATP and (C and D) AMP hydrolysis (n = 5). (E) Representative FACS analysis of Th17 cell survival (Annexin V-/PI-) in
the presence of graded doses of ATP. (F) Percentage of Th17 cell survival in the presence of ATP (n = 3). (G) IL-17-GFP
+ Th17TGF-β1 and Th17IL-23 cells were sorted and then analyzed by real-time PCR to assess mRNA encoding P2X7 receptor
(n = 4). Data are presented as mean ± S.E.M. *p<0.05 and **p<0.01 determined by Mann-Whitney test (B and D), two-way
analysis of variance (F) or t-test (G).
doi:10.1371/journal.pone.0157889.g003
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Fig 4. Th17TGF-β1 cells are less colitogenic than Th17IL-23 cells and produce IL-10 and IFN-γ in vivo. 1.3x106 IL-17-GFP+ Th17TGF-β1 and
Th17IL-23 cells were transferred to Rag1
-/- mice. (A) The weight of mice was measured over the course of 6 weeks after adoptive transfer of Th17
cells (n = 5–8 mice per group). (B) Colon length was measured 6 weeks following transfer of Th17 cells (n = 5). (C) Clinical score was calculated
based on weight loss and colon length 6 weeks after adoptive transfer of Th17 cells (n = 5). (D) Colonic histopathology. H&E and alcian blue
staining, original magnification 20X. Scale bar 100 μm (E) To determine intestinal cytokine production, intestinal tissues of Th17 recipient mice were
cultured for 24 hs at 37°C and 5%CO2 and production of several cytokines was analyzed by CBA (n = 6). (F and G) Representative FACS analysis
of IL-17, IL-10 and IFN-γ production by Th17TGF-β1 and Th17IL-23 cells 6 weeks after adoptive transfer to Rag1
-/- mice. Data are presented as
mean ± S.E.M. *p<0,05, **p<0,01 and ***p<0,001 comparing Th17TGF-β1 and Th17IL-23; ᵜᵜp<0,01 comparing PBS and Th17TGF-β1;
¤¤¤p<0,001
comparing PBS and Th17IL-23 determined by two-way analysis of variance (A). *p<0,05 determined by Kruskal-Wallis test (B,C and E).
doi:10.1371/journal.pone.0157889.g004
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CD39-mediated ATP hydrolysis is crucial for in vitro Th17 conversion to
IL-10 producing cells
To test the possibility that Th17TGF-β1 cells differentiate into IL-10-producing cells more effi-
ciently than Th17IL-23 cells, we reactivated IL-17 (GFP+) Th17 cells with anti-CD3 and anti-
CD28 antibodies for 3 days and evaluated IL-10 production in vitro. As shown in Fig 5A,
Th17TGF-β1 cells produced higher levels of IL-10 than Th17IL-23 cells following activation.
Moreover, the addition of TGF-β1, IL-21, and IL-27 (an improved cytokine cocktail to stimu-
late IL-10 production and Tr1 cell differentiation) during the reactivation increased the levels
of IL-10 production by Th17TGF-β1 cells.
Since it has been described that ATP inhibits naive T cell conversion to Tr1 cells via P2X7
receptor signaling [33], we tested whether CD39 and ATP hydrolysis is necessary for the con-
version of Th17 cells to Tr1 cells. For this, both subsets of Th17 cells were tested in their ability
to convert to IL-10-producing cells in the presence of Tr1 polarizing cytokines (TGF-β1/IL-21/
IL-27), ATP and the CD39 specific inhibitor, ARL67156. As shown in Fig 5A, the addition of
ATP reduced the ability of Th17TGF-β1 cells to produce IL-10 in the presence of ARL67156,
demonstrating that CD39 enzymatic activity is important for IL-10 production. Interestingly,
Th17IL-23 cells generated from P2X7 receptor knockout mice, produced higher levels of IL-10
when compared to Th17IL-23 cells generated from wild-type mice (Fig 5B). These results sug-
gest that CD39 enzymatic activity is crucial for limiting P2X7 receptor signaling in Th17 cells,
promoting the production of IL-10 and the conversion of Th17 cells into Tr1-like cells.
Fig 5. ATP hydrolysis by CD39 on Th17TGF-β1 cells promotes their conversion into IL-10-producing
cells. (A) IL-10 production by IL-17-GFP+ Th17TGF-β1 and Th17IL-23 cells restimulated for 3 days with anti-
CD3 and anti-CD28 antibodies in the presence and absence of Tr1 polarizing cytokines (TGF-β1, IL-21 and
IL-27), 50 μMATP and 250 μMARL67156. IL-10 production was analyzed by CBA (n = 4). (B) Th17IL-23 cells
from wild-type and P2X7R knockout mice were restimulated for 3 days with anti-CD3 and anti-CD28
antibodies and IL-10 production was analyzed by CBA (n = 3). Data are presented as mean ± S.E.M.
*p<0.05; **p<0.01 determined by repeated measures analysis of variance.
doi:10.1371/journal.pone.0157889.g005
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Discussion
Extracellular ATP (eATP) is a danger signal released by dying and damaged cells, and it func-
tions as an immunostimulatory signal that promotes inflammation [26,27]. CD39 and CD73
are two cell-surface ectoenzymes that dephosphorylate eATP into its metabolites, ADP, AMP,
and adenosine, in a tightly regulated process. CD39 catalyzes the conversion of eATP into
AMP, whereas CD73, catalyzes the dephosphorylation of AMP into adenosine [37–39]. The
coordinated action of these ectonucleotidases results in the generation of extracellular adeno-
sine, a molecule known for its immunosuppressive properties [40].
It has been described that the addition of TGF-β and IL-6 during the in vitro differentiation
of Th17 cells induces the expression of CD39 and CD73 ectonucleotidases by Th17 cells [34]
and that tumor-infiltrating Th17 cells may express these ectonucleotidases. Although the
expression of CD39 and CD73 ectonucleotidases has been related to their potential to generate
adenosine and create an immunosuppressive microenvironment [34], they may also serve to
deplete eATP. In this line of evidence, Falk and colleagues have reported that CD39 expression
by Foxp3+ regulatory T cells (Tregs) is involved in eATP depletion and reduces the cytotoxic
effects of this molecule [41]. Thus, CD39 expression may endow Tregs with the capacity to
enter into inflamed sites and mediate immunosuppression by preventing P2X7 receptor-medi-
ated cell death. Our results demonstrate that this mechanism may also be active on Th17 cells,
where ATP-induced cell death is reduced in the population of Th17 cells (Th17TGF-β1) express-
ing the CD39 ectonucleotidase. This result puts forward the idea that Th17 cells expressing
CD39 may survive in ATP-rich sites such as an inflamed tissue.
Th17 cells have been defined as a plastic subset of T cells, being able to differentiate into sev-
eral other T cell population during inflammation [42]. We and others have reported that Th17
cells can differentiate into IFN-γ-producing cells when transferred into lymphopenic hosts,
during EAE or in a murine melanoma model [11,13–15]. Moreover, Flavell and colleagues
have shown that Th17 cells are also able to differentiate into IL-10-producing Tr1 cells during
the resolution of inflammation and that this population of Tr1 cells present regulatory proper-
ties as they abolished Th17 cell-mediated colitis [20,21]. In this study, we confirmed that Th17
cells generated with TGF-β1 are a highly plastic subset of T helper cells, as they can differenti-
ate into IFN-γ-and IL-10-producing cells following transfer into Rag-/- mice.
Tr1 cells constitute an important subset of CD4+ T cells that help to control excessive
inflammatory responses mainly through the production of IL-10 [43]. It has been reported that
AHR and c-Maf transcription factors physically interact enabling the transactivation of the IL-
10 promoter and thus are involved the differentiation of Tr1 cells [44,45]. Importantly, eATP
and hypoxia have been shown to suppress the generation of Tr1 cells by triggering AHR inacti-
vation through HIF1-α [46]. It has been demonstrated that eATP increases the interaction of
HIF1-α to ARNT decreasing AHR binding to ARNT [33], resulting in the reduction of the
transcription of AHR controlled genes. Interestingly, the group of Quintana reported that
CD39 expression is important for the production of IL-10 by Tr1 cells as it allowed the deple-
tion of eATP favoring AHR/ARNT interaction [33]. Based on this evidence, we tested whether
CD39 may also play a role in promoting Th17 cell differentiation into IL-10-producing cells. In
agreement with this hypothesis, Th17 cells expressing the CD39 ectonucleotidase (Th17TGF-β1)
induce an IL-10-rich microenvironment when transferred in a setting of intestinal inflamma-
tion. Furthermore, Th17TGF-β1 cells produce higher levels of IL-10 compared to Th17IL-23 cells
when re-activated in vitro. Importantly, in the presence of eATP and the CD39 inhibitor
ARL67156 Th17TGF-β1 cells reduced their ability to produce IL-10.
Although we demonstrated adenosine production by Th17TGF-β1 cells, we could not detect a
strong suppressive activity of Th17 cells over effector T cells, which could be due to the strong
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activation stimulus we used to induce effector T cell activation. These results are different from
those reported by the group of Ghriringelli who suggest that adenosine produced by Th17 cells
have a suppressor activity [34]. Our data strongly argue in favor of the idea that CD39 may not
only be involved in generating a suppressive microenvironment, but also may deplete eATP
allowing these cells to survive into inflamed tissues. On the other hand, CD39 expression may
be a determining factor in the differentiation of Th17 cells to Tr1-like cells.
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S1 Fig. Th17 cells delay effector T cell proliferation in a contact-dependent manner.
Proliferation of effector CD4+ T cells during in vitro suppression assays with Th17TGF-β1 or
Th17IL-23 cells. Th17TGF-β1 or Th17IL-23 cells were sorted based on IL-17-GFP expression and
co-cultured for 3 days at different ratios with Violet-labeled CD4+ effector T cells from OT-II
mice activated with OVA323-339 and antigen presenting cells. (n = 3).
(TIF)
S2 Fig. Th17TGF-β1 and Th17IL-23 subsets present similar in vivo persistence. 1.3x10
6 IL-
17-GFP+ Th17TGF-β1 and Th17IL-23 cells were transferred to Rag1-/- mice and the percentage
of CD4+ CD3+ was analyzed 8 weeks after adoptive transfer in the spleen (A), mesenteric
lymph node (B) and small intestine lamina propria (C) (n = 6–7 mice per group). Data are pre-
sented as mean ± S.E.M.
(TIF)
Author Contributions
Conceived and designed the experiments: GU ALL RP CAC VG FJQMRBMR DS. Performed
the experiments: DF FFS JN FOB GT SN YHMJF DM GU. Analyzed the data: DF FFS FOB
GU. Contributed reagents/materials/analysis tools: ALL RP CAC VGMRBMR DS. Wrote the
paper: DF FFS SN FJQ MRBMR DS.
References
1. OuyangW, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflam-
mation. Immunity. 2008; 28: 454–67. doi: 10.1016/j.immuni.2008.03.004 PMID: 18400188
2. Khader S a, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity against
infectious diseases at the mucosa. Mucosal Immunol. 2009; 2: 403–11. doi: 10.1038/mi.2009.100
PMID: 19587639
3. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a
pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005; 201: 233–40.
PMID: 15657292
4. Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, et al. Monoclonal Anti-Interleu-
kin 23 Reverses Active Colitis in a T Cell-Mediated Model in Mice. Gastroenterology. 2007; 132: 2359–
2370. PMID: 17570211
5. Leppkes M, Becker C, Ivanov II, Hirth S, Wirtz S, Neufert C, et al. RORγ-Expressing Th17 Cells Induce
Murine Chronic Intestinal Inflammation via Redundant Effects of IL-17A and IL-17F. Gastroenterology.
2009; 136: 257–267. doi: 10.1053/j.gastro.2008.10.018 PMID: 18992745
6. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in
inflammatory bowel disease. Gut. 2003; 52: 65–71. PMID: 12477762
7. Nielsen OH, Kirman I, Rüdiger N, Hendel J, Vainer B. Upregulation of interleukin-12 and -17 in active
inflammatory bowel disease. Scand J Gastroenterol. 2003; 38: 180–185. PMID: 12678335
8. Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, et al. Role of the novel Th17 cytokine
IL-17F in inflammatory bowel disease (IBD): Upregulated colonic IL-17F expression in active Crohn’s
disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis. 2008; 14:
437–445. PMID: 18088064
Purinergic Signaling in Th17 Cell Plasticity
PLOS ONE | DOI:10.1371/journal.pone.0157889 June 20, 2016 14 / 16
9. Holtta V, Klemetti P, Sipponen T, Kociubinski G, Westerholm-Ormio M, Salo H, et al. IL-23/IL-17 immu-
nity as a hallmark of Crohn’s disease. InflammBowel Dis. 2008; 14: 1175–1184. doi: 10.1002/ibd.
20475 PMID: 18512248
10. Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, et al. IL23 differentially regu-
lates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut. 2008; 57: 1682–1689. doi:
10.1136/gut.2007.135053 PMID: 18653729
11. Nurieva R, Yang XO, Chung Y, Dong C. Cutting edge: in vitro generated Th17 cells maintain their cyto-
kine expression program in normal but not lymphopenic hosts. J Immunol. 2009; 182: 2565–8. doi: 10.
4049/jimmunol.0803931 PMID: 19234148
12. Feng T, Qin H, Wang L, Benveniste EN, Elson CO, Cong Y. Th17 cells induce colitis and promote Th1
cell responses through IL-17 induction of innate IL-12 and IL-23 production. J Immunol. 2011; 186:
6313–6318. doi: 10.4049/jimmunol.1001454 PMID: 21531892
13. Nuñez S, Saez JJ, Fernández D, Flores-Santibáñez F, Alvarez K, Tejon G, et al. T helper type 17 cells
contribute to anti-tumour immunity and promote the recruitment of T helper type 1 cells to the tumour.
Immunology. 2013; 139: 61–71. doi: 10.1111/imm.12055 PMID: 23278668
14. Muranski P, Boni A, Antony P a, Cassard L, Irvine KR, Kaiser A, et al. Tumor-specific Th17-polarized
cells eradicate large established melanoma. Blood. 2008; 112: 362–73. doi: 10.1182/blood-2007-11-
120998 PMID: 18354038
15. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, et al. Fate mapping of IL-17-producing T
cells in inflammatory responses. Nat Immunol. Nature Publishing Group; 2011; 12: 255–263. doi: 10.
1038/ni.1993 PMID: 21278737
16. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional
features of human Th17 cells. J Exp Med. 2007; 204: 1849–61. PMID: 17635957
17. Acosta-Rodriguez E V, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not
transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T
helper cells. Nat Immunol. 2007; 8: 942–949. PMID: 17676045
18. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, et al. TGF-beta
and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.
Nat Immunol. 2007; 8: 1390–7. PMID: 17994024
19. Xu J, Yang Y, Qiu G, Lal G, Wu Z, Levy DE, et al. c-Maf regulates IL-10 expression during Th17 polari-
zation. J Immunol. 2009; 182: 6226–36. doi: 10.4049/jimmunol.0900123 PMID: 19414776
20. Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, et al. Control of TH17 cells occurs in
the small intestine. Nature. 2011; 475: 514–8. doi: 10.1038/nature10228 PMID: 21765430
21. Gagliani N, Vesely MCA, Iseppon A, Brockmann L, Xu H, Palm NW, et al. Th17 cells transdifferentiate
into regulatory T cells during resolution of inflammation. Nature. 2015; 523: 221–225. doi: 10.1038/
nature14452 PMID: 25924064
22. Ghoreschi K, Laurence A, Yang X-P, Tato CM, McGeachy MJ, Konkel JE, et al. Generation of patho-
genic T(H)17 cells in the absence of TGF-β signalling. Nature. 2010; 467: 967–71. doi: 10.1038/
nature09447 PMID: 20962846
23. El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, Safavi F, et al. The encephalitogenicity of T(H)17 cells is
dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol. Nature Pub-
lishing Group; 2011; 12: 568–75. doi: 10.1038/ni.2031 PMID: 21516111
24. Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, et al. Induction and molecular signature of
pathogenic TH17 cells. Nat Immunol. 2012; 13: 991–9. doi: 10.1038/ni.2416 PMID: 22961052
25. Codarri L, Gyülvészi G, Tosevski V, Hesske L, Fontana A, Magnenat L, et al. RORγt drives production
of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neu-
roinflammation. Nat Immunol. 2011; 12: 560–7. doi: 10.1038/ni.2027 PMID: 21516112
26. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by
apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009; 461: 282–286.
doi: 10.1038/nature08296 PMID: 19741708
27. Trautmann A. Extracellular ATP in the immune system: more than just a “danger signal”. Sci Signal.
2009; 2: pe6. doi: 10.1126/scisignal.256pe6 PMID: 19193605
28. Cekic C, Linden J. Purinergic regulation of the immune system. Nat Rev Immunol. 2016; 16: 177–192.
doi: 10.1038/nri.2016.4 PMID: 26922909
29. Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, et al. ATP drives lamina propria
T(H)17 cell differentiation. Nature. 2008; 455: 808–12. doi: 10.1038/nature07240 PMID: 18716618
30. Aswad F, Kawamura H, Dennert G. High sensitivity of CD4+CD25+ regulatory T cells to extracellular
metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. J Immunol. 2005;
175: 3075–3083. PMID: 16116196
Purinergic Signaling in Th17 Cell Plasticity
PLOS ONE | DOI:10.1371/journal.pone.0157889 June 20, 2016 15 / 16
31. Jarvis MF, Khakh BS. ATP-gated P2X cation-channels. Neuropharmacology. 2009; 56: 208–215. doi:
10.1016/j.neuropharm.2008.06.067 PMID: 18657557
32. Deaglio S, Dwyer KM, GaoW, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by
CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;
204: 1257–65. PMID: 17502665
33. Mascanfroni ID, Takenaka MC, Yeste A, Patel B, Wu Y, Kenison JE, et al. Metabolic control of type 1
regulatory T cell differentiation by AHR and HIF1-α. Nat Med. 2015; 21: 638–46. doi: 10.1038/nm.3868
PMID: 26005855
34. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Végran F, Hichami A, et al. Stat3 and Gfi-1 transcrip-
tion factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expres-
sion. Immunity. 2012; 36: 362–73. doi: 10.1016/j.immuni.2011.12.019 PMID: 22406269
35. Gocke AR, Cravens PD, Ben L-H, Hussain RZ, Northrop SC, Racke MK, et al. T-bet regulates the fate
of Th1 and Th17 lymphocytes in autoimmunity. J Immunol. 2007; 178: 1341–1348. PMID: 17237380
36. Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, et al. Coexpression of
CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. 2013; 19: 739–46.
doi: 10.1038/nm.3179 PMID: 23624599
37. Robson SC, Sévigny J, Zimmermann H. The E-NTPDase family of ectonucleotidases: Structure func-
tion relationships and pathophysiological significance. Purinergic Signal. 2006; 2: 409–430. doi: 10.
1007/s11302-006-9003-5 PMID: 18404480
38. Beavis P a, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses.
Trends Immunol.2012; 33: 231–7. doi: 10.1016/j.it.2012.02.009 PMID: 22487321
39. Regateiro FS, Cobbold SP, Waldmann H. CD73 and adenosine generation in the creation of regulatory
microenvironments. Clin Exp Immunol. 2013; 171: 1–7. doi: 10.1111/j.1365-2249.2012.04623.x PMID:
23199317
40. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a Extracellular Adenosine Receptor-Mediated
Signaling in Adenosine-Mediated Inhibition of T-Cell Activation and Expansion. Blood. 1997; 90: 1600–
1610. PMID: 9269779
41. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of
ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppres-
sion. Blood. 2007; 110: 1225–32. PMID: 17449799
42. Annunziato F, Romagnani S. The transient nature of the Th17 phenotype. Eur J Immunol. 2010; 40:
3312–6. doi: 10.1002/eji.201041145 PMID: 21110314
43. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-
secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006; 212: 28–50. PMID:
16903904
44. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, et al. The aryl hydrocarbon receptor interacts
with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol.
Nature Publishing Group; 2010; 11: 854–861. doi: 10.1038/ni.1912 PMID: 20676095
45. Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, et al. Activation of the aryl hydrocarbon
receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol.
2010; 11: 846–53. doi: 10.1038/ni.1915 PMID: 20676092
46. Quintana FJ, Sherr DH. Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol Rev. 2013;
65: 1148–61. doi: 10.1124/pr.113.007823 PMID: 23908379
Purinergic Signaling in Th17 Cell Plasticity
PLOS ONE | DOI:10.1371/journal.pone.0157889 June 20, 2016 16 / 16
